FY2029 Earnings Estimate for NMRA Issued By William Blair

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Stock analysts at William Blair issued their FY2029 earnings per share estimates for Neumora Therapeutics in a research note issued on Thursday, January 2nd. William Blair analyst M. Minter expects that the company will post earnings of $1.47 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Royal Bank of Canada lowered shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $29.00 to $4.00 in a research note on Thursday, January 2nd. Bank of America decreased their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $2.48 on Monday. Neumora Therapeutics has a fifty-two week low of $1.83 and a fifty-two week high of $21.00. The firm has a market capitalization of $400.67 million, a PE ratio of -1.33 and a beta of 2.71. The stock’s 50-day simple moving average is $10.28 and its 200-day simple moving average is $11.46.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period last year, the firm earned ($1.14) EPS.

Institutional Trading of Neumora Therapeutics

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in Neumora Therapeutics by 54.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after purchasing an additional 694,385 shares in the last quarter. Barclays PLC boosted its position in Neumora Therapeutics by 352.9% during the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after acquiring an additional 100,678 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after acquiring an additional 406,891 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at about $1,097,000. Finally, Callan Capital LLC lifted its stake in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after purchasing an additional 456,207 shares in the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the completion of the sale, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at $342,303. This trade represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by corporate insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.